CORONA Remedies Q2 Results FY27: Revenue Jumps 22.16% to Rs 441.17 Cr, PAT Rs 60.31 Cr

CORONA Remedies Ltd (CORONA) Q2 Results FY27 announced on 30 October 2026, covering the company's financial performance for the July to September quarter. Revenue totalled Rs 441.17 Cr and PAT Rs 60.31 Cr. The CORONA Remedies Q2 Results FY27 filing sets the results date and the consolidated results side by side for the quarter.

The CORONA Remedies Q2 Results results analysis that follows looks at the financial highlights, the disclosed business drivers, the FY27 outlook and the risks. Univest starts it with the Financial Highlights table, which places the consolidated numbers against the quarter a year earlier.

Click Here – Get Free Investment Predictions

CORONA Remedies Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 441.17 Cr	Rs 361.13 Cr	+22.16% YoY
Operating Profit	Rs 95.95 Cr	Rs 78.47 Cr	+22.28% YoY
Net Profit (PAT)	Rs 60.31 Cr	Rs 52.32 Cr	+15.27% YoY

Source: company filing for CORONA Remedies Q2 Results FY27, 30 October 2026. Figures in Rs Crore, Consolidated basis.

Key Takeaways from CORONA Remedies Q2 Results: What Stands Out

• Revenue of Rs 441.17 Cr grew 22.16% YoY from Rs 361.13 Cr, the top line in the CORONA Remedies Q2 Results FY27 filing.
• Net profit of Rs 60.31 Cr is 15.27% higher than the Rs 52.32 Cr reported for the same quarter last year.
• Operating Profit of Rs 95.95 Cr grew 22.28% YoY, almost matching the pace of revenue growth.
• Return on equity of 27.36% and return on capital employed of 31.74% are the disclosed FY26 returns.
• Net profit grew more slowly than revenue, a gap the performance analysis examines in the next section.

CORONA Remedies Q2 Results FY27: Performance Analysis

CORONA Remedies posted consolidated revenue of Rs 441.17 Cr for July to September 2026, up 22.16% YoY, while net profit climbed 15.27% YoY to Rs 60.31 Cr. Read together, the CORONA Remedies Q2 Results FY27 figures show sales growing quicker than profit. Both the revenue and the net profit comparisons are drawn against the same July to September quarter a year earlier.

Operating Profit of Rs 95.95 Cr rose 22.28% YoY from Rs 78.47 Cr, a pace almost level with the 22.16% revenue growth, so the operating line kept up with sales. In this results analysis, net profit at 15.27% is therefore the slowest of the three YoY growth figures in the quarterly results.

For readers tracking CORONA Remedies Q2 Results, the supplied figures confirm the results but do not establish the specific cause of the gap between Operating Profit and net profit. The Rs 95.95 Cr Operating Profit and the Rs 60.31 Cr net profit are both supplied figures, and each should be read as reported. That is why the results analysis turns now to the business factors the disclosures list.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Revenue Growth – The results analysis opens with revenue, which grew 22.2% year on year to Rs 441.17 Cr in the latest quarter and forms the top line of the CORONA Remedies Q2 Results FY27 filing.

Net Profit – Net profit rose 15.3% year on year to Rs 60.31 Cr, a disclosed result that lags revenue growth but still sits above the year-earlier level in these quarterly results.

Return Ratios – Return on equity was 27.36% and return on capital employed was 31.74% in FY26, two disclosed full-year measures that give a longer-run reference beside the quarter's numbers.

FY27 Outlook After CORONA Remedies Q2 Results

CORONA Remedies will complete FY27 only after the remaining quarters are declared, so the full-year picture depends on later filings and disclosed conditions. The CORONA Remedies Q2 Results FY27 numbers cover a single consolidated quarter, and the results analysis keeps them in that frame without reading them as guidance. Later filings will add the remaining quarters of the year.

Revenue of Rs 441.17 Cr and net profit of Rs 60.31 Cr give later FY27 quarters a reference point. The Univest Screener helps readers follow each new filing, and the risks section next sets out the disclosed items to track.

Key Risks to Watch After CORONA Remedies Q2 Results FY27

Lower Return on Capital Employed

Return on capital employed declined to 31.74% in FY26 from 32.59% in FY25, a disclosed move that readers can set against the CORONA Remedies Q2 Results FY27 growth in revenue and profit.

Slower Annual Growth

Annual growth slowed to 23.9% in FY26 from 65.1% in FY25, a disclosed change in pace that sits beside the YoY growth recorded for this quarter.

Debt Relative to Assets

Debt was 0.19 times total assets in FY26, a disclosed balance sheet measure that investors can follow alongside the quarterly figures in later filings.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

CORONA Remedies Q2 Results FY27 show consolidated revenue of Rs 441.17 Cr and net profit of Rs 60.31 Cr, both above the year-earlier quarter. These quarterly results and consolidated results come from the 30 October 2026 declaration, and the CORONA Remedies Q2 Results data stands as a factual record of that quarter, with revenue growth of 22.16% and net profit growth of 15.27% as the two headline YoY figures. Investors should consult a SEBI-registered advisor before acting.

Frequently Asked Questions on CORONA Remedies Q2 Results FY27

What are CORONA Remedies Q2 Results FY27?

Ans. CORONA Remedies Q2 Results FY27 are the Consolidated quarterly results for July to September 2026, declared on 30 October 2026. They show revenue of Rs 441.17 Cr and net profit of Rs 60.31 Cr, as the introduction outlines.

What is the results date for CORONA Remedies Q2 Results FY27?

Ans. The results date for CORONA Remedies was 30 October 2026, for the July to September 2026 quarter, which means it agrees with the date stated in the Quick Answer near the top of this article.

What revenue was reported in CORONA Remedies Q2 Results FY27?

Ans. CORONA Remedies Q2 Results FY27 report revenue of Rs 441.17 Cr, up 22.16% YoY from Rs 361.13 Cr. Alongside this, the Financial Highlights table lays out each supplied revenue figure for the quarter.

What net profit was reported in CORONA Remedies Q2 Results FY27?

Ans. CORONA Remedies reported net profit of Rs 60.31 Cr in CORONA Remedies Q2 Results FY27, against Rs 52.32 Cr a year earlier, so the Key Takeaways section records a rise of 15.27%.

How much YoY growth did revenue show in CORONA Remedies Q2 Results FY27?

Ans. Revenue showed YoY growth of 22.16% for CORONA Remedies, while net profit grew 15.27%, which means sales rose faster than profit, as the Performance Analysis section explains.

Did net profit rise or fall in CORONA Remedies Q2 Results?

Ans. Net profit rose in CORONA Remedies Q2 Results, from Rs 52.32 Cr to Rs 60.31 Cr, a 15.27% YoY increase, and the Performance Analysis shows it as the slowest of the three growth figures.

What was the Operating Profit in CORONA Remedies Q2 Results FY27?

Ans. Operating Profit in CORONA Remedies Q2 Results FY27 was Rs 95.95 Cr, up 22.28% from Rs 78.47 Cr a year earlier, which means it grew at nearly the same pace as revenue.

Are CORONA Remedies Q2 Results consolidated results or standalone results?

Ans. CORONA Remedies Q2 Results are consolidated results, so the figures cover the company on a consolidated basis, which means revenue of Rs 441.17 Cr and net profit of Rs 60.31 Cr reflect that scope, as the introduction states.

What business factors shaped CORONA Remedies Q2 Results FY27?

Ans. The disclosed factors are revenue growth of 22.2%, a net profit rise of 15.3%, a return on equity of 27.36% and a return on capital employed of 31.74% in FY26, as the Key Business Factors section lists.

What are the key risks after CORONA Remedies Q2 Results FY27?

Ans. The key risks are a lower FY26 return on capital employed, slower annual growth of 23.9% and debt of 0.19 times total assets, which the Key Risks section explains one by one.

What is the outlook after CORONA Remedies Q2 Results?

Ans. The outlook rests on later FY27 quarters, so full-year results will depend on subsequent declarations, as the FY27 Outlook section explains, alongside the Rs 441.17 Cr revenue base from this quarter.

Where can I find the complete CORONA Remedies Q2 Results FY27 data?

Ans. The complete data sits in the Financial Highlights table earlier in this article on Univest, which means revenue, Operating Profit and net profit appear there together with their YoY changes.